Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 9, 2021

Primary Completion Date

December 2, 2022

Study Completion Date

June 21, 2023

Conditions

Covid19

Interventions

BIOLOGICAL

AdCLD-CoV19-1

Replication deficient adenoviral vector based COVID-19 prevention vaccine containing recombinant gene of SARS-CoV-2 spike protein

Trial Locations (3)

Korea University Ansan Hospital, Ansan

The Catholic University of Korea, ST. Vincent's Hospital, Suwon

Korea University Guro Hospital, Seoul

All Listed Sponsors

lead

Cellid Co., Ltd.

INDUSTRY

NCT05047692 - Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers | Biotech Hunter | Biotech Hunter